Skip to main content

Table 2 Predictors of HBeAg status among patients with HIV-HBV co-infection: Univariate analyses

From: Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

  HBeAg
Non-reagent
HBeAg
Reagent
OR 95%CI p
Sex      0. 59
female 2 (66. 67%) 1 (33. 33%) 1. 00   
male 42(50. 60%) 41 (49. 40%) 1. 95 0. 17-22. 37  
Age      0. 16
< = 42 years 18 (43. 9%) 23 (56. 1%) 1. 00   
> 42 years 26 (59. 09%) 18 (40. 91%) 0. 54 0. 22-1. 28  
CD4      
< 350 cels/μ1 12 (46. 15%) 14 (53. 85%) 1. 00   0. 54
> 350 cels/μ1 32 (53. 33%) 28 (46. 67%) 0. 75 0. 29-1. 88  
Use of ARV      0. 18
no 1(20%) 4 (80%) 1. 00   
yes 43 (53. 09%) 38 (46. 91%) 0. 22 0. 02-2. 06  
HBV Genotype      0. 68
A 5 (23. 8%) 16 (78. 1%) 0. 58 0. 1-3. 2  
Non-A 2 (19. 3%) 11 (84. 6) 1. 00   
Previous use of LAM      0. 64
no 3 (42. 8%) 4 (57. 1%) 1. 00   
yes 41(51. 9%) 38 (48. 10%) 0. 69 0. 14-3. 31  
Previous use of TDF      
no 22 (57. 8%) 16 (42. 11%) 1. 00   0. 26
yes 22 (45. 8%) 26 (54. 1%) 1. 62 0. 68-3. 83  
Time of TDF use > 12 months      0. 73
no 6 (50%) 6 (50%) 1. 00   
yes 16 (44. 4%) 20 (55. 5%) 1. 25 0. 33-4. 62  
HBV-DNA      < 0. 001
< 60 UI/mL 34(40. 9%) 15(18%) 1. 00   
> 60 UI/mL 08(9. 6%) 26(31. 3%) 21. 52 4. 58-100. 98  
ALT Level      0. 002
Normal 39(46. 9%) 24(28. 9%) 1. 00   
> 1. 5 × ULN 4(4. 8%) 16(19. 2) 6. 66 1. 99-22. 28  
Compliance to therapy      0. 26
yes 41 (53. 25%) 36 (46. 75%) 1. 00   
no 3 (33. 3%) 6 (66. 6%) 2. 27 0. 53-9. 77  
  1. ULN-Upper Limit of Normality